Published in Lancet on January 16, 1988
Pathogenesis of human immunodeficiency virus infection. Microbiol Rev (1993) 5.88
Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci U S A (1995) 4.37
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
Novel mutation in the human immunodeficiency virus type 1 reverse transcriptase gene that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine. J Virol (1992) 3.46
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidine. Antimicrob Agents Chemother (1992) 3.11
Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1994) 2.81
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother (1992) 2.58
Anti-human immunodeficiency virus type 1 activity and in vitro toxicity of 2'-deoxy-3'-thiacytidine (BCH-189), a novel heterocyclic nucleoside analog. Antimicrob Agents Chemother (1991) 2.40
Differential phosphorylation of azidothymidine, dideoxycytidine, and dideoxyinosine in resting and activated peripheral blood mononuclear cells. J Clin Invest (1993) 2.27
Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex. Nat Med (2011) 2.11
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides. J Exp Med (1988) 2.08
The development of antiretroviral therapy and its impact on the HIV-1/AIDS pandemic. Antiviral Res (2009) 2.03
Changes in drug sensitivity of human immunodeficiency virus type 1 during therapy with azidothymidine, dideoxycytidine, and dideoxyinosine: an in vitro comparative study. Proc Natl Acad Sci U S A (1993) 1.92
Marked in vivo antiretrovirus activity of 9-(2-phosphonylmethoxyethyl)adenine, a selective anti-human immunodeficiency virus agent. Proc Natl Acad Sci U S A (1989) 1.74
Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One (2010) 1.44
Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrob Agents Chemother (1995) 1.31
Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase. Antimicrob Agents Chemother (1998) 1.29
Synergistic inhibition of replication of human immunodeficiency virus type 1, including that of a zidovudine-resistant isolate, by zidovudine and 2',3'-dideoxycytidine in vitro. Antimicrob Agents Chemother (1992) 1.25
Oxathiin carboxanilide, a potent inhibitor of human immunodeficiency virus reproduction. Proc Natl Acad Sci U S A (1991) 1.24
Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides. Antimicrob Agents Chemother (1994) 1.22
Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription. Antimicrob Agents Chemother (1996) 1.16
In vivo antiviral activity and pharmacokinetics of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine in woodchuck hepatitis virus-infected woodchucks. Antimicrob Agents Chemother (1997) 1.14
Effects of 2',3'-dideoxynucleosides on proliferation and differentiation of human pluripotent progenitors in liquid culture and their effects on mitochondrial DNA synthesis. Antimicrob Agents Chemother (1994) 1.13
In vitro inhibition of human immunodeficiency virus (HIV) type 1 replication by C2 symmetry-based HIV protease inhibitors as single agents or in combinations. Antimicrob Agents Chemother (1992) 1.13
Inhibition of human immunodeficiency virus type 1 reverse transcriptase by the 5'-triphosphate beta enantiomers of cytidine analogs. Antimicrob Agents Chemother (1994) 1.12
Activities of (-)-carbovir and 3'-azido-3'-deoxythymidine against human immunodeficiency virus in vitro. Antimicrob Agents Chemother (1990) 1.08
Dipyridamole potentiates the inhibition by 3'-azido-3'-deoxythymidine and other dideoxynucleosides of human immunodeficiency virus replication in monocyte-macrophages. Proc Natl Acad Sci U S A (1989) 1.05
Combinatorial approaches to the prevention and treatment of HIV-1 infection. Antimicrob Agents Chemother (2011) 1.04
Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate. Antimicrob Agents Chemother (1989) 1.00
Lipophilic halogenated congeners of 2',3'-dideoxypurine nucleosides active against human immunodeficiency virus in vitro. Proc Natl Acad Sci U S A (1990) 0.97
Antiviral therapy: current concepts and practices. Clin Microbiol Rev (1992) 0.96
Human immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugs. J Virol (1993) 0.94
Alternating versus continuous drug regimens in combination chemotherapy of human immunodeficiency virus type 1 infection in vitro. Antimicrob Agents Chemother (1994) 0.93
In vitro inhibition of the infectivity and replication of human immunodeficiency virus type 1 by combination of antiretroviral 2',3'-dideoxynucleosides and virus-binding inhibitors. Antimicrob Agents Chemother (1990) 0.92
Pharmacokinetics, oral bioavailability, and metabolic disposition in rats of (-)-cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl] cytosine, a nucleoside analog active against human immunodeficiency virus and hepatitis B virus. Antimicrob Agents Chemother (1993) 0.92
Antiretroviral therapy: reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.92
Cyclobut-A and cyclobut-G, carbocyclic oxetanocin analogs that inhibit the replication of human immunodeficiency virus in T cells and monocytes and macrophages in vitro. Antimicrob Agents Chemother (1990) 0.90
Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2',3'-dideoxyinosine in infected resting human lymphocytes. Proc Natl Acad Sci U S A (1994) 0.89
Targeting antiretroviral nucleoside analogues in phosphorylated form to macrophages: in vitro and in vivo studies. Proc Natl Acad Sci U S A (1992) 0.88
Effects of U-75875, a peptidomimetic inhibitor of retroviral proteases, on simian immunodeficiency virus infection in rhesus monkeys. Antimicrob Agents Chemother (1994) 0.88
In vitro bone marrow toxicity of nucleoside analogs against human immunodeficiency virus. Antimicrob Agents Chemother (1989) 0.86
Human immunodeficiency virus inhibition is prolonged by 3'-azido-3'-deoxythymidine alternating with 2',3'-dideoxycytidine compared with 3'-azido-3'-deoxythymidine alone. Antimicrob Agents Chemother (1989) 0.86
Toxicity and efficacy of 2',3'-dideoxycytidine in clinical trials of pigtailed macaques infected with simian retrovirus type 2. Antimicrob Agents Chemother (1989) 0.86
Emergence of aminoglycoside resistance genes aadA and aadE in the genus Campylobacter. Antimicrob Agents Chemother (1990) 0.85
Antiretroviral therapy: strategies beyond single-agent reverse transcriptase inhibition. Antimicrob Agents Chemother (1992) 0.85
Susceptibilities of zidovudine-resistant variants of human immunodeficiency virus type 1 to inhibition by acyclic nucleoside phosphonates. Antimicrob Agents Chemother (1994) 0.84
Structure-activity relationships of fluorinated nucleoside analogs and their synergistic effect in combination with phosphonoformate against human immunodeficiency virus type 1. Antimicrob Agents Chemother (1989) 0.84
In vitro and in vivo evidence that the antiviral activity of 2',3'-dideoxycytidine is target cell dependent in a feline retrovirus animal model. Antimicrob Agents Chemother (1990) 0.83
Effects of incarceration on HIV-infected individuals. J Natl Med Assoc (1996) 0.83
Differential inhibition of 2'-deoxycytidine salvage as a possible mechanism for potentiation of the anti-human immunodeficiency virus activity of 2',3'-dideoxycytidine by dipyridamole. Antimicrob Agents Chemother (1991) 0.83
Inhibition of infectivity of human immunodeficiency virus by a novel nucleoside, oxetanocin, and related compounds. Antimicrob Agents Chemother (1989) 0.83
Molecular modeling approach to understanding the mode of action of L-nucleosides as antiviral agents. Antimicrob Agents Chemother (2001) 0.82
2',3'-Dideoxycytidine metabolism in a new drug-resistant cell line. Biochem J (1995) 0.79
In vitro potency of inhibition by antiviral drugs of hematopoietic progenitor colony formation correlates with exposure at hemotoxic levels in human immunodeficiency virus-positive humans. Antimicrob Agents Chemother (1996) 0.79
Zalcitabine population pharmacokinetics: application of radioimmunoassay. Antimicrob Agents Chemother (1998) 0.78
Comparative metabolism of the antiviral dimer 3'-azido-3'-deoxythymidine-P-2',3'-dideoxyinosine and the monomers zidovudine and didanosine by rat, monkey, and human hepatocytes. Antimicrob Agents Chemother (1997) 0.77
Production of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine from 2',3'-dideoxyuridine and the corresponding purine bases by resting cells of Escherichia coli AJ 2595. Appl Environ Microbiol (1989) 0.77
Correlation of neuromuscular pathology in acquired immune deficiency syndrome patients with cytomegalovirus infection and zidovudine treatment. Acta Neuropathol (1992) 0.77
Phosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected mice. Antimicrob Agents Chemother (1994) 0.76
AIDS and the lung. 2--Antiretroviral treatment in human immunodeficiency virus disease. Thorax (1989) 0.75
Poster communications. Br J Pharmacol (1993) 0.75
Effects of antiretroviral dideoxynucleosides on polymorphonuclear leukocyte function. Antimicrob Agents Chemother (1990) 0.75
2'3'-Dideoxycytidine-induced thymic lymphoma correlates with species-specific suppression of a subpopulation of primitive hematopoietic progenitor cells in mouse but not rat or human bone marrow. J Clin Invest (1995) 0.75
Early versus delayed treatment of HIV infection. Zidovudine should be given before symptoms develop. Drugs (1995) 0.75
2',3'-Dideoxycytidine Protects Dopaminergic Neurons in a Mouse Model of Parkinson's Disease. Neurochem Res (2017) 0.75
A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med (1997) 17.51
The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 13.84
The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med (1987) 8.52
Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. JAMA (2000) 6.49
Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA (1997) 6.35
Plasma viremia in human immunodeficiency virus infection. N Engl J Med (1989) 5.73
Antiretroviral therapy for HIV infection in 1996. Recommendations of an international panel. International AIDS Society-USA. JAMA (1996) 5.29
Administration of 3'-azido-3'-deoxythymidine, an inhibitor of HTLV-III/LAV replication, to patients with AIDS or AIDS-related complex. Lancet (1986) 5.05
Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. JAMA (1998) 4.61
Seropositivity for HIV and the development of AIDS or AIDS related condition: three year follow up of the San Francisco General Hospital cohort. Br Med J (Clin Res Ed) (1988) 4.03
Evaluation of heterosexual partners, children, and household contacts of adults with AIDS. JAMA (1987) 3.99
Long latency precedes overt seroconversion in sexually transmitted human-immunodeficiency-virus infection. Lancet (1987) 3.68
Tuberculosis, atypical mycobacteriosis, and the acquired immunodeficiency syndrome among Haitian and non-Haitian patients in south Florida. Ann Intern Med (1984) 3.25
Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet (1986) 2.92
Plasma and cerebrospinal fluid pharmacokinetics of 3'-azido-3'-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther (1987) 2.92
In vivo activity against HIV and favorable toxicity profile of 2',3'-dideoxyinosine. Science (1989) 2.70
A comparison of immediate with deferred zidovudine therapy for asymptomatic HIV-infected adults with CD4 cell counts of 500 or more per cubic millimeter. AIDS Clinical Trials Group. N Engl J Med (1995) 2.66
Tuberculosis symposium: emerging problems and promise. J Infect Dis (1993) 2.55
European guidelines on the clinical management of HIV-1 tropism testing. Lancet Infect Dis (2011) 2.47
Opportunistic infections and Kaposi's sarcoma among Haitians: evidence of a new acquired immunodeficiency state. Ann Intern Med (1983) 2.45
CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy. Ann Intern Med (1991) 2.35
Response of human-immunodeficiency-virus-associated neurological disease to 3'-azido-3'-deoxythymidine. Lancet (1987) 2.30
Reversal of adriamycin resistance by verapamil in human ovarian cancer. Science (1984) 2.24
Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study. Ann Intern Med (1992) 2.19
Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi's sarcoma: results of a randomized phase III clinical trial. J Clin Oncol (1998) 2.12
Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med (1997) 2.06
Nocardiosis in 30 patients with advanced human immunodeficiency virus infection: clinical features and outcome. Clin Infect Dis (1994) 2.06
Transfusion transmission of human T-lymphotropic virus types I and II: serologic and polymerase chain reaction results in recipients identified through look-back investigations. Transfusion (1993) 2.03
Mothers of infants with the acquired immunodeficiency syndrome. Evidence for both symptomatic and asymptomatic carriers. JAMA (1985) 2.02
Long-term toxicity/activity profile of 2',3'-dideoxyinosine in AIDS or AIDS-related complex. Lancet (1990) 2.02
Pharmacokinetics of 2',3'-dideoxyadenosine and 2',3'-dideoxyinosine in patients with severe human immunodeficiency virus infection. Clin Pharmacol Ther (1990) 1.87
Platelets fixed with paraformaldehyde: a new reagent for assay of von Willebrand factor and platelet aggregating factor. J Lab Clin Med (1975) 1.82
Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood (1997) 1.81
Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med (1984) 1.80
Plasma concentrations of midazolam in children following intranasal administration. Anesthesiology (1991) 1.77
Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. Stat Med (1993) 1.62
Effects of zidovudine therapy in minority and other subpopulations with early HIV infection. JAMA (1991) 1.62
Corticosteroids as adjunctive therapy for severe Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A double-blind, placebo-controlled trial. N Engl J Med (1990) 1.61
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol (1993) 1.61
Clinical importance of HCV confirmatory testing in blood donors. Lancet (1992) 1.58
Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus (HIV) infection and zidovudine therapy. Overview of four clinical trials. Ann Intern Med (1992) 1.53
Pharmacokinetics of 2',3'-dideoxycytidine in patients with AIDS and related disorders. J Clin Pharmacol (1988) 1.51
Use of whole blood methods in assessment of immune parameters in immunodeficiency states. Diagn Clin Immunol (1987) 1.51
1,2,3-Triazole-[2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D- ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"-oxathiole 2",2"-dioxide) (TSAO) analogues: synthesis and anti-HIV-1 activity. J Med Chem (1994) 1.50
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. J Clin Oncol (1987) 1.50
CD4 cell count as a surrogate endpoint in HIV clinical trials: a meta-analysis of studies of the AIDS Clinical Trials Group. AIDS (1998) 1.49
A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion (2000) 1.48
Screening for viral markers in volunteer and replacement blood donors in West Africa. Vox Sang (2001) 1.47
Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem Biophys Res Commun (1989) 1.46
Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol (1989) 1.45
An index predicting relapse and need for hospitalization in patients with acute bronchial asthma. N Engl J Med (1981) 1.45
Portal levels and hepatic clearance of 5-fluorouracil after intraperitoneal administration in humans. Cancer Res (1981) 1.45
Pyrimidine dideoxyribonucleosides: selectivity of penetration into cerebrospinal fluid. J Pharmacol Exp Ther (1988) 1.43
Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med (2006) 1.43
Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrob Agents Chemother (2000) 1.42
Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection. Ann Intern Med (1993) 1.42
Factors determining the activity of 2',3'-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol (1988) 1.38
Characterization of the antigenic determinants and host components in immune complexes from patients with secondary syphilis. J Immunol (1986) 1.38
Effects of suramin on HTLV-III/LAV infection presenting as Kaposi's sarcoma or AIDS-related complex: clinical pharmacology and suppression of virus replication in vivo. Lancet (1985) 1.35
Patterns of serological markers in transfusion-transmitted hepatitis C virus infection using second-generation HCV assays. J Med Virol (1992) 1.33
Population pharmacokinetics of nevirapine, zidovudine, and didanosine in human immunodeficiency virus-infected patients. The National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group Protocol 241 Investigators. Antimicrob Agents Chemother (1999) 1.32
Increasing prevalence of non-clade B HIV-1 strains in heterosexual men and women, as monitored by analysis of reverse transcriptase and protease sequences. J Acquir Immune Defic Syndr (2001) 1.31
Preparation and characterization of an intravenous solution of IgG from human immunodeficiency virus-seropositive donors. Blood (1991) 1.30
Oxidative stress and neuroAIDS: triggers, modulators and novel antioxidants. Trends Neurosci (2001) 1.30
Updated European recommendations for the clinical use of HIV drug resistance testing. Antivir Ther (2004) 1.28
A randomized, controlled, double-blind study comparing the survival benefit of four different reverse transcriptase inhibitor therapies (three-drug, two-drug, and alternating drug) for the treatment of advanced AIDS. AIDS Clinical Trial Group 193A Study Team. J Acquir Immune Defic Syndr Hum Retrovirol (1998) 1.28
Alteration of zidovudine pharmacokinetics by probenecid in patients with AIDS or AIDS-related complex. Clin Pharmacol Ther (1989) 1.27
Dynamics and modulation of human immunodeficiency virus type 1 transcripts in vitro and in vivo. J Virol (1996) 1.27
ICU survival of patients with the acquired immunodeficiency syndrome. Crit Care Med (1986) 1.24
Markers of HIV infection prior to IgG antibody seropositivity. JAMA (1989) 1.24
Screening of selected male blood donors for p24 antigen of human immunodeficiency virus type 1. The Transfusion Safety Study Group. N Engl J Med (1990) 1.22
A sensitive viral capture assay for detection of plasma viremia in HIV-infected individuals. AIDS Res Hum Retroviruses (1992) 1.21
Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis (1998) 1.20
Letter: Prothrombin-complex concentrate in treatment of classical haemophilia with factor-VIII antibody. Lancet (1975) 1.19
Prevalence of HTLV-III/LAV antibodies in patients with hemophilia and in their sexual partners in France. N Engl J Med (1986) 1.19
Serological and molecular screening for viruses in blood donors from Ntcheu, Malawi: high prevalence of HIV-1 subtype C and of markers of hepatitis B and C viruses. J Med Virol (2001) 1.19
Redefining the HIV-infectious window period in the chimpanzee model: evidence to suggest that viral nucleic acid testing can prevent blood-borne transmission. Transfusion (1999) 1.19
Predictors of virologic and clinical outcomes in HIV-1-infected patients receiving concurrent treatment with indinavir, zidovudine, and lamivudine. AIDS Clinical Trials Group Protocol 320. Ann Intern Med (2001) 1.18
The initial immune response to HIV and immune system activation determine the outcome of HIV disease. J Acquir Immune Defic Syndr (1991) 1.18
Kaposi's sarcoma of the tracheobronchial tree. Clinical, bronchoscopic, and pathologic features. Chest (1985) 1.18
Human immunodeficiency virus antigenemia in patients with AIDS and AIDS-related disorders: a comparison between European and Central African populations. J Infect Dis (1987) 1.17
Quantitative analysis of HIV-1 proviral DNA in peripheral blood mononuclear cells from patients with AIDS or ARC: decrease of proviral DNA content following treatment with 2',3'-dideoxyinosine (ddI). AIDS Res Hum Retroviruses (1990) 1.17
Activity of acyclic nucleoside phosphonate analogues against human immunodeficiency virus in monocyte/macrophages and peripheral blood lymphocytes. Biochem Biophys Res Commun (1991) 1.16
2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5''-(4''-amino-1'',2''- oxathiole-2'',2'-dioxide)pyrimidine (TSAO) nucleoside analogues: highlyselective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc Natl Acad Sci U S A (1992) 1.14
Activity of the (R)-enantiomers of 9-(2-phosphonylmethoxypropyl)-adenine and 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine against human immunodeficiency virus in different human cell systems. Biochem Biophys Res Commun (1996) 1.13
Dextran sulfate is poorly absorbed after oral administration. Ann Intern Med (1989) 1.13
The dynamics of hepatitis C virus binding to platelets and 2 mononuclear cell lines. Blood (2001) 1.13
Initial clinical experience with dideoxynucleosides as single agents and in combination therapy. Ann N Y Acad Sci (1990) 1.12
Anti-retroviral therapy of human immunodeficiency virus infection: current strategies and challenges for the future. Blood (1991) 1.12
Poor sensitivity, specificity, and reproducibility of detection of HIV-1 DNA in serum by polymerase chain reaction. The Transfusion Safety Study Group. J Acquir Immune Defic Syndr (1992) 1.12
Alternating and intermittent regimens of zidovudine and dideoxycytidine in patients with AIDS or AIDS-related complex. Ann Intern Med (1993) 1.11